Compare Fiverr International Ltd (FVRR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Fiverr International Ltd trades at $8.56 (market cap $307.38M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 3.2× Fiverr International Ltd's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FVRR | MRVI | |
|---|---|---|
Market Cap | $307.38M | $977.37M |
Volume | 937,489 | 2,742,564 |
Sector | Media | Health |
52-Week High | $23.60 | $9.00 |
52-Week Low | $8.47 | $2.83 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $59.76M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.60, down 0.23% with a bearish technical signal. The company shows improving fundamentals with revenue growth from $391M in 2024 to $431M in 2025 and net income margin expanding to 7.18%. Recent Q2 2026 earnings missed expectations, and AI disruption is compressing demand for lower-value freelance work. Analyst consensus is cautious with 76% hold ratings despite attractive valuation multiples including P/E of 10.56 and P/S of 0.75.
The outlook remains challenged by AI-driven market shifts, though current valuations appear discounted. Key risks include sustained revenue pressure from AI adoption and competitive threats. Upside potential exists if Fiverr successfully adapts its platform to the evolving gig economy, with analyst price targets suggesting 22% upside to the $10.50 consensus.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
